Related Experiment Videos
Isoniazid prophylaxis in lung transplantation.
1Servei de Pneumologia, Hospital General Vall d'Hebron, Barcelona, Spain. aroman@hg.vhebron.es
Summary
Lung transplant recipients have a higher risk of tuberculosis. Isoniazid prophylaxis was found to be safe and protective against tuberculous disease in infected and anergic patients awaiting lung transplantation.
Area of Science:
- Medicine
- Pulmonology
- Infectious Diseases
Background:
- Tuberculous disease (TD) incidence is elevated in lung-transplant recipients compared to the general population.
- Lung transplantation candidates require effective preventive strategies against TD, especially in endemic areas.
Purpose of the Study:
- To evaluate the safety and efficacy of isoniazid prophylaxis in lung transplant candidates.
- To assess TD incidence in infected-anergic versus non-infected patients undergoing lung transplantation.
Main Methods:
- A prospective study involving 61 lung transplant candidates over 7 years.
- Isoniazid prophylaxis administered to infected and anergic patients on the waiting list.
- Monitoring for the development of tuberculous disease.
Main Results:
- Six out of 61 patients (10%) developed tuberculosis during the study period.
- No significant difference in TD incidence was observed between infected-anergic and non-infected patients.
- Isoniazid prophylaxis was deemed safe for use in this patient cohort.
Conclusions:
- Isoniazid prophylaxis is a safe and effective strategy to prevent tuberculous disease in infected and anergic lung transplant candidates.
- This preventive measure is crucial for patients in tuberculous-endemic regions undergoing lung transplantation.
- The protocol demonstrated protective benefits for high-risk individuals.